<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="drugDebug/PMC7091548/results/search/disease/results.xml">
  <result pre="10.1155/2020/5984095 : Research Article Application of Optimal Control to Influenza" exact="Pneumonia" post="Coinfection with Antiviral Resistance https://orcid.org/0000-0001-5745-4650KanyiriCaroline W.kanyiricarolyne2@gmail.com1LuboobiLivingstone2KimathiMark3[], 1[], 2[], 3"/>
  <result pre="Application of Optimal Control to Influenza Pneumonia Coinfection with Antiviral" exact="Resistance" post="https://orcid.org/0000-0001-5745-4650KanyiriCaroline W.kanyiricarolyne2@gmail.com1LuboobiLivingstone2KimathiMark3[], 1[], 2[], 3 Academic Editor: Chung-Min Liao"/>
  <result pre="provided the original work is properly cited. Abstract Influenza and" exact="pneumonia" post="independently lead to high morbidity and mortality annually among"/>
  <result pre="human population globally; however, a glaring fact is that influenza" exact="pneumonia" post="coinfection is more vicious and it is a threat"/>
  <result pre="a deterministic mathematical model illustrating the transmission dynamics of influenza" exact="pneumonia" post="coinfection is formulated having incorporated antiviral resistance. Optimal control"/>
  <result pre="that implementation of prevention measures is sufficient to eradicate influenza" exact="pneumonia" post="coinfection from a given population. The prevention measures could"/>
  <result pre="the influenza virus. 1. Introduction Clinical evidence points out that" exact="infection" post="with a particular combination of pathogens results in an"/>
  <result pre="with a particular combination of pathogens results in an aggravated" exact="infection" post="with more severe clinical outcome compared with infection with"/>
  <result pre="an aggravated infection with more severe clinical outcome compared with" exact="infection" post="with either pathogen alone [1]. This is specially true"/>
  <result pre="for influenza virus and bacterium Streptococcus pneumoniae [2–4]. Influenza and" exact="pneumonia" post="each contributes greatly to the global burden of morbidity"/>
  <result pre="and leads to high death toll, typically over a relatively" exact="short" post="period of time [5–8]. Streptococcus pneumoniae, Haemophilus influenzae, and"/>
  <result pre="intolerance, and can be detrimental to the diagnosis of the" exact="disease" post="[12]. According to [13], it can be difficult to"/>
  <result pre="[13], it can be difficult to identify influenza patients experiencing" exact="bacterial" post="coinfections due to symptom overlap of influenza and bacterial"/>
  <result pre="experiencing bacterial coinfections due to symptom overlap of influenza and" exact="bacterial infections." post="In [14], it is indicated that a strong index"/>
  <result pre="that the majority of deaths were as a result of" exact="secondary" post="bacterial pneumonia. Data from the subsequent 1957, 1968, and"/>
  <result pre="the majority of deaths were as a result of secondary" exact="bacterial" post="pneumonia. Data from the subsequent 1957, 1968, and 2009"/>
  <result pre="predisposes them to invasion by pneumococcus rendering a mild influenza" exact="infection" post="severe or even fatal. This could be through several"/>
  <result pre="even fatal. This could be through several ways such as" exact="epithelial" post="damage, changes in airway function, upregulation and exposure of"/>
  <result pre="have been carried out to investigate the time course of" exact="susceptibility to" post="Streptococcus pneumoniae after influenza virus infection. Results revealed that"/>
  <result pre="the time course of susceptibility to Streptococcus pneumoniae after influenza" exact="virus infection." post="Results revealed that on average, individuals developed coinfection within"/>
  <result pre="on average, individuals developed coinfection within 6 days after influenza" exact="virus infection" post="[20–23]. Emergence of drug resistance, which has become a"/>
  <result pre="average, individuals developed coinfection within 6 days after influenza virus" exact="infection" post="[20–23]. Emergence of drug resistance, which has become a"/>
  <result pre="drug resistance, which has become a global concern, complicates influenza" exact="pneumonia" post="coinfection even more. Drug resistance refers to the ability"/>
  <result pre="the conventional treatment procedure ineffective. This leads to persistence of" exact="infections" post="in the body, hence increasing the risk of spread"/>
  <result pre="in use as most of the circulating influenza viruses have" exact="acquired" post="resistance to M2 ion-channel inhibitors [27, 28]. Moreover, many"/>
  <result pre="inhibitors [27, 28]. Moreover, many circulating influenza viruses have also" exact="acquired" post="resistance to neuraminidase (NA) inhibitors [28, 29] raising an"/>
  <result pre="resistance continues to threaten effective prevention and treatment of influenza" exact="pneumonia" post="coinfection. In addition, the cost of health care for"/>
  <result pre="addition, the cost of health care for patients with resistant" exact="infections" post="is much higher than care for patients with nonresistant"/>
  <result pre="infections is much higher than care for patients with nonresistant" exact="infections" post="especially due to longer duration of illness. Strategies such"/>
  <result pre="are necessary in order to curb the spread of various" exact="infectious diseases." post="However, if they are not administered at the right"/>
  <result pre="and in the right amount, curtailing the spread of the" exact="infectious diseases" post="remains a difficult task. The application of optimal control"/>
  <result pre="study of pneumonia, for instance, in [35]. Given that influenza" exact="pneumonia" post="coinfection is more disastrous than either of the single"/>
  <result pre="pneumonia coinfection is more disastrous than either of the single" exact="infections" post="alone, this paper seeks to investigate optimal control strategies"/>
  <result pre="paper seeks to investigate optimal control strategies for the influenza" exact="pneumonia" post="coinfection and in the emergence of antiviral resistance. 2."/>
  <result pre="Model Formulation The model presented in this paper has the" exact="total" post="population subdivided into eight compartments. These are susceptible (S),"/>
  <result pre="influenza strain (IR), infected with both wild-type influenza strain and" exact="pneumonia" post="(Iwp), infected with both resistant influenza strain and pneumonia"/>
  <result pre="and pneumonia (Iwp), infected with both resistant influenza strain and" exact="pneumonia" post="(IRp), recovered from influenza (Rz), recovered from pneumonia (Rp),"/>
  <result pre="strain and pneumonia (IRp), recovered from influenza (Rz), recovered from" exact="pneumonia" post="(Rp), and recovered from both influenza and pneumonia (Rzp)."/>
  <result pre="recovered from pneumonia (Rp), and recovered from both influenza and" exact="pneumonia" post="(Rzp). In the model, individuals are first infected with"/>
  <result pre="individuals are first infected with influenza virus and then contract" exact="bacterial" post="pneumonia. An assumption is made that there is no"/>
  <result pre="bacterial pneumonia. An assumption is made that there is no" exact="primary" post="bacterial pneumonia infection. Individuals enter the population via immigration"/>
  <result pre="pneumonia. An assumption is made that there is no primary" exact="bacterial" post="pneumonia infection. Individuals enter the population via immigration at"/>
  <result pre="An assumption is made that there is no primary bacterial" exact="pneumonia" post="infection. Individuals enter the population via immigration at the"/>
  <result pre="strain and those infected with influenza resistant strain can contract" exact="secondary" post="bacterial pneumonia at the rate of λ3 with the"/>
  <result pre="and those infected with influenza resistant strain can contract secondary" exact="bacterial" post="pneumonia at the rate of λ3 with the force"/>
  <result pre="those infected with influenza resistant strain can contract secondary bacterial" exact="pneumonia" post="at the rate of λ3 with the force of"/>
  <result pre="pneumonia at the rate of λ3 with the force of" exact="infection" post="of pneumonia being βp(Iwp+IRp). Parameter βp refers to the"/>
  <result pre="the rate of λ3 with the force of infection of" exact="pneumonia" post="being βp(Iwp+IRp). Parameter βp refers to the transmission rate"/>
  <result pre="respectively. Individuals infected with both the wild-type influenza strain and" exact="pneumonia" post="and those infected with both resistant strain and pneumonia"/>
  <result pre="and pneumonia and those infected with both resistant strain and" exact="pneumonia" post="can recover from either influenza alone at rates of"/>
  <result pre="influenza alone at rates of α3 and α4, respectively, or" exact="pneumonia" post="alone at rates of ϕ1 and ϕ2, respectively, or"/>
  <result pre="ϕ1 and ϕ2, respectively, or recover from both influenza and" exact="pneumonia" post="at rates of ω1 and ω2, respectively. This means"/>
  <result pre="have pneumonia. Rz class is however considered noninfectious given that" exact="bacterial" post="pneumonia is considered weakly infectious after antimicrobials are administered."/>
  <result pre="pneumonia. Rz class is however considered noninfectious given that bacterial" exact="pneumonia" post="is considered weakly infectious after antimicrobials are administered. On"/>
  <result pre="however considered noninfectious given that bacterial pneumonia is considered weakly" exact="infectious" post="after antimicrobials are administered. On the other hand, the"/>
  <result pre="from Iwp and IRp classes that have only recovered from" exact="pneumonia" post="but may still have influenza. Given that the infectious"/>
  <result pre="from pneumonia but may still have influenza. Given that the" exact="infectious" post="period of influenza is about seven days after symptoms"/>
  <result pre="δ4, respectively. Those infected with both wild-type influenza strain and" exact="pneumonia" post="could also develop antiviral resistance and progress to IRp"/>
  <result pre="who have recovered from influenza, pneumonia, and both influenza and" exact="pneumonia" post="lose their immunity and become susceptible again at rates"/>
  <result pre="equations, with nonnegative initial conditions, describes the dynamics of influenza" exact="pneumonia" post="coinfection: (1) d S d t = π +"/>
  <result pre="a mathematical optimal control problem is formulated and analysed. Influenza" exact="pneumonia" post="coinfection model (1) is extended to include time-dependent control"/>
  <result pre="wild-type influenza strain, resistant influenza strain, and pneumonia, respectively. The" exact="infection" post="prevalence reduction could be through social distancing, vaccination, curbing"/>
  <result pre="published estimates of morbidity and mortality rates resulting from influenza" exact="pneumonia" post="coinfection in the middle- and low-income countries. On the"/>
  <result pre="&amp;lt;5 years and adults &amp;gt;60 years. Studies show that influenza" exact="pneumonia" post="coinfection affects people of all ages; however, the morbidity"/>
  <result pre="to give an indication of the likely dynamics of influenza" exact="pneumonia" post="coinfection, baseline parameter values were used for the simulations."/>
  <result pre="only in an attempt to curb the spread of influenza" exact="pneumonia" post="coinfection. From Figure 2, it can be observed that"/>
  <result pre="with and without the treatment efforts, the wild-type influenza and" exact="pneumonia" post="coinfection persists in the population. Without any controls, it"/>
  <result pre="that the number of individuals coinfected with resistant influenza and" exact="pneumonia" post="increases initially and then decreases slowly but not to"/>
  <result pre="strategies in place, the number of the infected individuals is" exact="lower" post="but not significant and does not decrease to zero"/>
  <result pre="strategy is not effective in curbing the spread of influenza" exact="pneumonia" post="coinfection. As explained in details in [4, 49–51], treatment"/>
  <result pre="collection and false negative results when viruses replicate in the" exact="lower" post="respiratory tract. In addition, treatment often aggravates development of"/>
  <result pre="and false negative results when viruses replicate in the lower" exact="respiratory" post="tract. In addition, treatment often aggravates development of resistance."/>
  <result pre="strategies, the number of individuals coinfected with wild-type influenza and" exact="pneumonia" post="decreases to zero. Similarly, from Figure 5, it can"/>
  <result pre="the number of individuals coinfected with resistant influenza strain and" exact="pneumonia" post="decreases drastically right from the beginning to zero by"/>
  <result pre="strategies, the number of individuals coinfected with wild-type influenza and" exact="pneumonia" post="decreases right from the beginning and it is at"/>
  <result pre="strategies, the number of individuals coinfected with resistant influenza and" exact="pneumonia" post="significantly decreases and it is inconsequential at day 30"/>
  <result pre="place, the number of individuals coinfected with wild-type influenza and" exact="pneumonia" post="decreases to zero by day 30. It can also"/>
  <result pre="applied, the number of individuals coinfected with resistant influenza and" exact="pneumonia" post="drastically decreases, and by about day 28, the number"/>
  <result pre="the implementation of prevention measures only, which include and not" exact="limited" post="to social distancing, vaccination, curbing mutation and reassortment, and"/>
  <result pre="reassortment, and curbing interspecies movement of the influenza virus, influenza" exact="pneumonia" post="coinfection can be eradicated from a given population. Compared"/>
  <result pre="strategies are more effective in curbing the spread of influenza" exact="pneumonia" post="coinfection; hence, the public health sector and other stake"/>
  <result pre="M.AsharH. K.ChowV. T.TeluguakulaN.Lethal synergism between influenza and streptococcus pneumoniaeJournal of" exact="Infectious" post="Pulmonary Diseases20162210.16966/2470-3176.114 3SmithA. M.AdlerF. R.RibeiroR. M.et al.Kinetics of coinfection"/>
  <result pre="K.ChowV. T.TeluguakulaN.Lethal synergism between influenza and streptococcus pneumoniaeJournal of Infectious" exact="Pulmonary" post="Diseases20162210.16966/2470-3176.114 3SmithA. M.AdlerF. R.RibeiroR. M.et al.Kinetics of coinfection with"/>
  <result pre="death estimate increases worldwide2017https://www.cdc.gov/media/releases/2017/p1213-flu-death-estimate.html 7ThomasK.Global burden of pneumoniaInternational Journal of" exact="Infectious" post="Diseases201645110.1016/j.ijid.2016.02.027 8collab: UNICEFStatistics by topic/pneumonia2018https://data.unicef.org/topic/child-health/pneumonia/ 9MorrisD. E.ClearyD. W.ClarkeS. C.Secondary"/>
  <result pre="Infectious Diseases201645110.1016/j.ijid.2016.02.027 8collab: UNICEFStatistics by topic/pneumonia2018https://data.unicef.org/topic/child-health/pneumonia/ 9MorrisD. E.ClearyD. W.ClarkeS. C.Secondary" exact="bacterial infections" post="associated with influenza pandemicsFrontiers in Microbiology20178p. 104110.3389/fmicb.2017.01041 10GuptaR. K.GeorgeR.Nguyen-Van-TamJ."/>
  <result pre="Diseases201645110.1016/j.ijid.2016.02.027 8collab: UNICEFStatistics by topic/pneumonia2018https://data.unicef.org/topic/child-health/pneumonia/ 9MorrisD. E.ClearyD. W.ClarkeS. C.Secondary bacterial" exact="infections" post="associated with influenza pandemicsFrontiers in Microbiology20178p. 104110.3389/fmicb.2017.01041 10GuptaR. K.GeorgeR.Nguyen-Van-TamJ."/>
  <result pre="associated with influenza pandemicsFrontiers in Microbiology20178p. 104110.3389/fmicb.2017.01041 10GuptaR. K.GeorgeR.Nguyen-Van-TamJ. S.Bacterial" exact="pneumonia" post="and pandemic influenza planningEmerging Infectious Diseases20081481187119210.3201/eid1408.07075118680640 11McCullersJ. A.Insights into"/>
  <result pre="Microbiology20178p. 104110.3389/fmicb.2017.01041 10GuptaR. K.GeorgeR.Nguyen-Van-TamJ. S.Bacterial pneumonia and pandemic influenza planningEmerging" exact="Infectious" post="Diseases20081481187119210.3201/eid1408.07075118680640 11McCullersJ. A.Insights into the interaction between influenza virus"/>
  <result pre="interaction between influenza virus and pneumococcusClinical Microbiology Reviews200619357158210.1128/cmr.00058-0516847087 12LiX.-X.ZhouX.-N.Co-infection of" exact="tuberculosis" post="and parasitic diseases in humans: a systematic reviewParasites &amp;amp;"/>
  <result pre="&amp;amp; vectors201361p. 79 13KleinE. Y.MonteforteB.GuptaA.et al.The frequency of influenza and" exact="bacterial" post="coinfection: a systematic review and meta-analysisInfluenza and Other Respiratory"/>
  <result pre="and bacterial coinfection: a systematic review and meta-analysisInfluenza and Other" exact="Respiratory" post="Viruses201610539440310.1111/irv.1239827232677 14AroraA.KrishnaswamyU.MoideenR.PadmajaM.Tubercular and bacterial coinfection: a case seriesLung India:"/>
  <result pre="systematic review and meta-analysisInfluenza and Other Respiratory Viruses201610539440310.1111/irv.1239827232677 14AroraA.KrishnaswamyU.MoideenR.PadmajaM.Tubercular and" exact="bacterial" post="coinfection: a case seriesLung India: Official Organ of Indian"/>
  <result pre="Indian Chest Society2015322p. 17210.4103/0970-2113.152645 15MorensD. M.TaubenbergerJ. K.FauciA. S.Predominant role of" exact="bacterial" post="pneumonia as a cause of death in pandemic influenza:"/>
  <result pre="Chest Society2015322p. 17210.4103/0970-2113.152645 15MorensD. M.TaubenbergerJ. K.FauciA. S.Predominant role of bacterial" exact="pneumonia" post="as a cause of death in pandemic influenza: implications"/>
  <result pre="in pandemic influenza: implications for pandemic influenza preparednessThe Journal of" exact="Infectious" post="Diseases2008198796297010.1086/59170818710327 16WeinbergerD. M.SimonsenL.JordanR.SteinerC.MillerM.ViboudC.Impact of the 2009 influenza pandemic on"/>
  <result pre="Infectious Diseases2008198796297010.1086/59170818710327 16WeinbergerD. M.SimonsenL.JordanR.SteinerC.MillerM.ViboudC.Impact of the 2009 influenza pandemic on" exact="pneumococcal pneumonia" post="hospitalizations in the United StatesThe Journal of Infectious Diseases2011205345846510.1093/infdis/jir74922158564"/>
  <result pre="Diseases2008198796297010.1086/59170818710327 16WeinbergerD. M.SimonsenL.JordanR.SteinerC.MillerM.ViboudC.Impact of the 2009 influenza pandemic on pneumococcal" exact="pneumonia" post="hospitalizations in the United StatesThe Journal of Infectious Diseases2011205345846510.1093/infdis/jir74922158564"/>
  <result pre="on pneumococcal pneumonia hospitalizations in the United StatesThe Journal of" exact="Infectious" post="Diseases2011205345846510.1093/infdis/jir74922158564 17GrabowskaK.HögbergL.PenttinenP.SvenssonÅ.EkdahlK.Occurrence of invasive pneumococcal disease and number of"/>
  <result pre="United StatesThe Journal of Infectious Diseases2011205345846510.1093/infdis/jir74922158564 17GrabowskaK.HögbergL.PenttinenP.SvenssonÅ.EkdahlK.Occurrence of invasive pneumococcal" exact="disease" post="and number of excess cases due to influenzaBMC Infectious"/>
  <result pre="pneumococcal disease and number of excess cases due to influenzaBMC" exact="Infectious" post="Diseases200661p. 5810.1186/1471-2334-6-58 18MichelowI. C.OlsenK.LozanoJ.et al.Epidemiology and clinical characteristics of"/>
  <result pre="Diseases200661p. 5810.1186/1471-2334-6-58 18MichelowI. C.OlsenK.LozanoJ.et al.Epidemiology and clinical characteristics of community-acquired" exact="pneumonia" post="in hospitalized childrenPediatrics2004113470170710.1542/peds.113.4.70115060215 19ShresthaS.FoxmanB.BerusJ.et al.The role of influenza in"/>
  <result pre="G.Both influenza-induced neutrophil dysfunction and neutrophil-independent mechanisms contribute to increased" exact="susceptibility to" post="a secondary streptococcus pneumoniae infectionInfection and Immunity200674126707672110.1128/iai.00789-0616982840 22van der"/>
  <result pre="dysfunction and neutrophil-independent mechanisms contribute to increased susceptibility to a" exact="secondary" post="streptococcus pneumoniae infectionInfection and Immunity200674126707672110.1128/iai.00789-0616982840 22van der SluijsK. F.van"/>
  <result pre="J. R.NijhuisM.et al.Il-10 is an important mediator of the enhanced" exact="susceptibility to" post="pneumococcal pneumonia after influenza infectionThe Journal of Immunology2004172127603760910.4049/jimmunol.172.12.760315187140 23ShresthaS.FoxmanB.DawidS.et"/>
  <result pre="al.Il-10 is an important mediator of the enhanced susceptibility to" exact="pneumococcal pneumonia" post="after influenza infectionThe Journal of Immunology2004172127603760910.4049/jimmunol.172.12.760315187140 23ShresthaS.FoxmanB.DawidS.et al.Time and"/>
  <result pre="is an important mediator of the enhanced susceptibility to pneumococcal" exact="pneumonia" post="after influenza infectionThe Journal of Immunology2004172127603760910.4049/jimmunol.172.12.760315187140 23ShresthaS.FoxmanB.DawidS.et al.Time and"/>
  <result pre="infectionThe Journal of Immunology2004172127603760910.4049/jimmunol.172.12.760315187140 23ShresthaS.FoxmanB.DawidS.et al.Time and dose-dependent risk of" exact="pneumococcal pneumonia" post="following influenza: a model for within-host interaction between influenza"/>
  <result pre="Journal of Immunology2004172127603760910.4049/jimmunol.172.12.760315187140 23ShresthaS.FoxmanB.DawidS.et al.Time and dose-dependent risk of pneumococcal" exact="pneumonia" post="following influenza: a model for within-host interaction between influenza"/>
  <result pre="Resistance201710p. 12110.2147/idr.s105473 29MontoA. S.Implications of antiviral resistance of influenza virusesClinical" exact="Infectious" post="Diseases200948439739910.1086/59631219586376 30LeeJ.KimJ.KwonH.-D.Optimal control of an influenza model with seasonal"/>
  <result pre="of Biomathematics2017105p. 175006810.1142/s1793524517500681 35TilahunG. T.MakindeO. D.MalonzaD.Modelling and optimal control of" exact="pneumonia" post="disease with cost-effective strategiesJournal of Biological Dynamics201711sup240042610.1080/17513758.2017.133724528613986 36PontryaginL.BoltyanskiiV.GamkrelidzeR. V.MischenkoE."/>
  <result pre="Biomathematics2017105p. 175006810.1142/s1793524517500681 35TilahunG. T.MakindeO. D.MalonzaD.Modelling and optimal control of pneumonia" exact="disease" post="with cost-effective strategiesJournal of Biological Dynamics201711sup240042610.1080/17513758.2017.133724528613986 36PontryaginL.BoltyanskiiV.GamkrelidzeR. V.MischenkoE. F.The"/>
  <result pre="and symptoms of influenza–health professionals2016https://www.cdc.gov/flu/professionals/acip/clinical.htm 43DavisB. M.AielloA. E.DawidS.RohaniP.ShresthaS.FoxmanB.Influenza and community-acquired" exact="pneumonia" post="interactions: the impact of order and time of infection"/>
  <result pre="community-acquired pneumonia interactions: the impact of order and time of" exact="infection" post="on population patternsAmerican Journal of Epidemiology2012175536336710.1093/aje/kwr40222247048 44LambertN. D.OvsyannikovaI. G.PankratzV."/>
  <result pre="systems biology approachExpert Review of Vaccines201211898599410.1586/erv.12.6123002979 45ImranM.MalikT.AnsariA. R.KhanA.Mathematical analysis of" exact="swine influenza" post="epidemic model with optimal controlJapan Journal of Industrial and"/>
  <result pre="(Gho) Data–Life Expectancy2016Geneva, SwitzerlandWHO 47ClaraW.ArmeroJ.RodriguezD.et al.Estimated incidence of influenza-virus-associated severe" exact="pneumonia" post="in children in El Salvador, 2008–2010Bulletin of the World"/>
  <result pre="Organization20129075676310.2471/BLT.11.09820223109743 48MeterskyM. L.MastertonR. G.LodeH.FileT. M.JrBabinchakT.Epidemiology, microbiology, and treatment considerations for" exact="bacterial" post="pneumonia complicating influenzaInternational Journal of Infectious Diseases2012165e321e33110.1016/j.ijid.2012.01.00322387143 49CawcuttK.KalilA. C.Pneumonia"/>
  <result pre="48MeterskyM. L.MastertonR. G.LodeH.FileT. M.JrBabinchakT.Epidemiology, microbiology, and treatment considerations for bacterial" exact="pneumonia" post="complicating influenzaInternational Journal of Infectious Diseases2012165e321e33110.1016/j.ijid.2012.01.00322387143 49CawcuttK.KalilA. C.Pneumonia with"/>
  <result pre="and treatment considerations for bacterial pneumonia complicating influenzaInternational Journal of" exact="Infectious" post="Diseases2012165e321e33110.1016/j.ijid.2012.01.00322387143 49CawcuttK.KalilA. C.Pneumonia with bacterial and viral coinfectionCurrent Opinion"/>
  <result pre="pneumonia complicating influenzaInternational Journal of Infectious Diseases2012165e321e33110.1016/j.ijid.2012.01.00322387143 49CawcuttK.KalilA. C.Pneumonia with" exact="bacterial" post="and viral coinfectionCurrent Opinion in Critical Care201723538539010.1097/mcc.000000000000043528777158 50MosconaA.Neuraminidase inhibitors"/>
  <result pre="influenzaInternational Journal of Infectious Diseases2012165e321e33110.1016/j.ijid.2012.01.00322387143 49CawcuttK.KalilA. C.Pneumonia with bacterial and" exact="viral" post="coinfectionCurrent Opinion in Critical Care201723538539010.1097/mcc.000000000000043528777158 50MosconaA.Neuraminidase inhibitors for influenzaNew"/>
  <result pre="for influenzaNew England Journal of Medicine2005353131363137310.1056/nejmra05074016192481 51McCullersJ. A.Preventing and treating" exact="secondary" post="bacterial infections with antiviral agentsAntiviral Therapy201116212313510.3851/imp173021447860 Figure 1 Schematic"/>
  <result pre="influenzaNew England Journal of Medicine2005353131363137310.1056/nejmra05074016192481 51McCullersJ. A.Preventing and treating secondary" exact="bacterial infections" post="with antiviral agentsAntiviral Therapy201116212313510.3851/imp173021447860 Figure 1 Schematic diagram showing"/>
  <result pre="England Journal of Medicine2005353131363137310.1056/nejmra05074016192481 51McCullersJ. A.Preventing and treating secondary bacterial" exact="infections" post="with antiviral agentsAntiviral Therapy201116212313510.3851/imp173021447860 Figure 1 Schematic diagram showing"/>
  <result pre="diagram showing population flow between different epidemiological classes for influenza" exact="pneumonia" post="coinfection. Figure 2 Individuals coinfected with wild-type influenza and"/>
  <result pre="Transmission rate of resistant influenza strain βp Transmission rate of" exact="pneumonia" post="α1 Recovery rate of influenza for individuals in Iw"/>
  <result pre="influenza for individuals in IRp class ϕ1 Recovery rate of" exact="pneumonia" post="for individuals in Iwp class ϕ2 Recovery rate of"/>
  <result pre="pneumonia for individuals in Iwp class ϕ2 Recovery rate of" exact="pneumonia" post="for individuals in IRp class ω1 Recovery rate of"/>
  <result pre="in IRp class ω1 Recovery rate of both influenza and" exact="pneumonia" post="for individuals in Iwp class ω2 Recovery rate of"/>
  <result pre="in Iwp class ω2 Recovery rate of both influenza and" exact="pneumonia" post="for individuals in IRp class ϑ1, ϑ2, ϑ3 Rate"/>
  <result pre="resistant influenza strain 0.00026 day−1 Assumed βp Transmission rate of" exact="pneumonia" post="0.000162 day−1 Reference [41] α1 Recovery rate of influenza"/>
  <result pre="in IRp class 0.0222 day−1 Assumed ϕ1 Recovery rate of" exact="pneumonia" post="for individuals in Iwp class 0.033 day−1 Reference [41]"/>
  <result pre="Iwp class 0.033 day−1 Reference [41] ϕ2 Recovery rate of" exact="pneumonia" post="for individuals in IRp class 0.033 day−1 Reference [41]"/>
  <result pre="day−1 Reference [41] ω1 Recovery rate of both influenza and" exact="pneumonia" post="for individuals in Iwp class 0.0166 day−1 Assumed ω2"/>
  <result pre="0.0166 day−1 Assumed ω2 Recovery rate of both influenza and" exact="pneumonia" post="for individuals in IRp class 0.0166 day−1 Assumed ϑ1"/>
  <result pre="0.00833 day−1 Reference [44] ϑ2 Rate of losing immunity for" exact="pneumonia" post="0.00833 day−1 Assumed ϑ3 Rate of losing immunity for"/>
  <result pre="0.00833 day−1 Assumed ϑ3 Rate of losing immunity for influenza" exact="pneumonia" post="coinfection 0.00833 day−1 Assumed b Rate of developing antiviral"/>
 </snippets>
</snippetsTree>
